ROCHE INVESTING $70 MIL. IN GENOMICS TECHNOLOGY VIA MILLENNIUM
Executive Summary
ROCHE INVESTING $70 MIL. IN GENOMICS TECHNOLOGY VIA MILLENNIUM Pharmaceuticals, which will collaborate with Hoffmann- La Roche in the development of small molecules to treat obesity and Type II diabetes. Under the agreement, announced March 30, Roche receives worldwide rights to small molecule therapeutics resulting from the research and exclusive rights to antisense, protein and gene therapies outside North America.